Why Does My Eye Injection Need Prior Authorization Every Time?
Eye Injection Approvals at a Glance
Contact your eye doctor's office the same day, and go to an emergency room if you cannot reach them, for any of these:
- Eye pain that is getting worse rather than settling.
- Vision that is getting worse, or a new dark patch.
- A red eye with discharge, or increasing redness after the first day.
- A sudden shower of new floaters, or flashing lights.
- A curtain or shadow across your sight.
Most such calls turn out to be ordinary irritation that settles. A few catch an infection or a retinal tear early, when there is most to be gained by acting.
Your plan is not questioning your diagnosis. It is re-checking a drug it treats as high cost. Most plans re-check on a schedule, not just once. Carriers apply prior authorization to anti-VEGF medicines because of the volume and the high dollar cost of those medicines. Commercial plans, Medicare Advantage plans, and Medicaid HMO plans all commonly use these policies1. So the repeat is by design. It is not a sign that something went wrong with your case.
Prior authorization is your plan's advance permission for a specific medicine, on a specific date, for a specific eye. Your doctor's office sends the diagnosis, the scan findings, and the treatment history. The plan compares that against its own coverage policy and answers yes or no. These policies vary significantly from carrier to carrier and change frequently1. That is why the office cannot simply learn one rule and apply it to everyone.
Most approvals are time limited or dose limited, so the office has to ask again. In a study across 9 United States retina practices, 64 of every 100 prior authorization requests were reauthorizations for a medicine the patient was already receiving2. So the repeat request is the most common kind, not an unusual one. Your treatment has not been downgraded. The paperwork clock has run out again.
Most of the time it means nothing you will notice. In that same study, about 96 of every 100 requests were approved2. The more common effect is timing rather than refusal. Among approved requests, about 60 of every 100 still involved a delay of more than 24 hours, while about 40 of every 100 were approved the same day2. Ask the office when your authorization expires, so a gap is spotted before it costs you an appointment.
The Injections and Medicines These Rules Cover
These are injections into the jelly of the eye, to control leaking or growing blood vessels. Intravitreal injections are used for neovascular age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, geographic atrophy, uveitis, and swelling of the central retina3. All are long running conditions. That is why treatment is a course rather than a one time event, and why the paperwork recurs.
Several drugs do a similar job at very different prices, and that price gap drives the rules. Aflibercept (Eylea) and ranibizumab (Lucentis) are among the medicines given as an injection into the eye3. Brolucizumab (Beovu) and faricimab (Vabysmo) are given the same way, along with biosimilar versions of ranibizumab and aflibercept, which are close copies of an existing biologic medicine3. Your plan may prefer a biosimilar because it costs the plan less.
One widely used option is given off-label, and that is not a scandal. Bevacizumab (Avastin) is listed as off-label among the medicines given by injection into the eye, meaning it is used outside the uses printed on its own label3. Off-label use is legal and common in medicine. It also costs far less than the other injection options, which is why many plans want it tried first. Ask your doctor which medicine fits your eye, and why.
The schedule itself explains a lot of the repeat paperwork. Early in treatment, people may need injections and follow up every month, and later, once the disease is stable, some doctors extend the gap between injections3. A monthly cycle can mean a plan review several times a year. As your interval stretches out, the authorization cycle often stretches with it.
How the Prior Authorization Process Works, Step by Step
The office submits your diagnosis code, the medicine and dose, your scan results, and what you have already tried. The plan checks that packet against its coverage policy for that drug. A missing scan is a common reason a request bounces back, so your scans matter administratively as well as clinically. You do not submit any of this yourself.
Deadlines depend on your plan type, and on a detail most people are never told. Under a federal rule, from January 2026 Medicare Advantage, Medicaid, and CHIP plans must decide standard prior authorization requests within 7 calendar days and expedited requests within 72 hours4. That rule did not change the timeframes for Marketplace plans, which generally have 15 days for a standard decision and 72 hours for an expedited one, although a state may set shorter limits4. Most employer-sponsored plans are not covered by that rule4. Those deadlines are a real step forward, but they may not cover your injection, for the reason in the next section.
Injected eye medicines are drugs, and the 2026 deadlines were written for items and services. Prescription drugs are excluded from that final rule, and CMS said it would consider future rulemaking after receiving many objections to the exclusion4. A separate rule proposed in April 2026 would set prior authorization standards for drugs, and the payers it would cover include Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and Marketplace plans on the federal exchanges. The proposed compliance date is October 1, 2027. CMS does not propose new decision timeframes for Medicare Advantage organizations or Part D sponsors, pointing to the requirements that already apply to Part B and Part D drugs5. That is a proposal, not settled policy, and none of it applies unless it is finalized. So if your injection sits under Medicare Advantage, the deadlines already in place are the ones to plan around.
If you are in a Medicare Advantage plan, one protection already exists for injected drugs. Medicare Advantage plans are required to respond to an expedited prior authorization request for a Part B drug within 24 hours4. That word expedited matters. It applies when waiting the standard time could seriously harm your health, and your doctor is the one who says so. Ask the office whether your request qualifies.
Step therapy is the rule behind most refusals on these medicines. It requires a lower cost preferred drug for injection, typically Avastin, to be tried first, with a documented failed response, before a preferred alternative such as Eylea or Lucentis is authorized1. Step therapy accounted for 65 of 2,225 requests being denied, about 3 of every 1002. Small as a share, it is the most common single reason a request is turned down.
Which Plans Use These Rules, and What Protects You
This is the protection most worth knowing, and it is often not explained. People already taking a Part B covered medicine cannot be required to switch to their Medicare Advantage plan's preferred drug, because step therapy applies only when a current or new enrollee starts a new medicine6. If you are told at a renewal that you must change to a cheaper injection you have already been on, that is worth questioning rather than accepting.
You can read the rules before they surprise you. Medicare Advantage plans must disclose their step therapy rules in the Annual Notice of Change and in the Evidence of Coverage, and a plan that applies Part B step therapy has to offer a drug management care coordination program that includes medication review and consultation6. Those two documents arrive every fall. The injection section is worth finding before you choose a plan for the following year.
What to Settle With the Office at Your Visit
A short conversation at the desk saves most of the scrambling later. Ask when your authorization expires, which medicine it covers, and who to call if your next appointment is at risk. Ask whether your plan requires step therapy. If it does, ask what has been documented about medicines you have already tried. Write the answers down.
It is usually not your doctor. Most retina practices have staff dedicated to authorizations, and they can tell you where a request is sitting. Each request took a median of 100 minutes of clinic staff time in the 9 practice study2. That helps set expectations, and explains why a same day answer is not always possible even when everyone is trying.
Call the office if your injection date is close and you have heard nothing, if a denial letter arrives, or if your appointment is cancelled without a new date. Ask three things: what the plan said, what the office is doing next, and by when. A polite, specific call moves a stalled request more reliably than waiting.
If Your Plan Says No
A vague denial is no longer acceptable from the plans the federal rule covers. Plans must give a specific reason for a denial to both the doctor and the patient, and must publicly report which services need authorization along with aggregated approval and denial rates4. Ask for that reason in writing. It determines the fix, because a missing scan is solved differently from a step therapy rule.
An exception request asks the plan to waive its own rule for your situation. Enrollees have the right to request an exception to a step therapy requirement, and to appeal if the exception is refused6. The strongest exception requests are clinical and specific: what happened when you were on the preferred drug, what your scans showed, and why your doctor recommends the other medicine. Your doctor writes this, not you.
You do not have to wait in the standard queue when waiting is the risk. A person whose doctor believes their health could be seriously harmed by waiting the standard time for a decision may ask for their appeal to be decided on an expedited timeline6. Say plainly that you are asking for expedited handling, and ask the office to support it with your doctor's reasoning. Getting that label right is what changes the deadline the plan must meet.
You do not have to do this alone or pay anyone to help. For further questions about appeals, enrollees are encouraged to contact their local State Health Insurance Assistance Program6. The authorization staff can also tell you what has been sent and what is outstanding. If a denial letter is unclear, ask the plan's member services line to explain it and to confirm your appeal deadline while you are on the call.
Medical Reasons Your Injection Might Be Postponed
Some delays are clinical decisions, and those are made in your interest. Your doctor may postpone an injection for a medical reason, such as a concern about infection around the eye, or something found at that day's examination. This is a different situation from an authorization delay. Ask which kind of delay you are in, because the person who can fix it is different in each case.
Mention any recent eye infection, a red or sticky eye, recent eye surgery, or a new eye injury. Mention blood thinners, and any allergy to iodine or to the anesthetic used. None of these automatically stops an injection. They change how your team prepares, and they are far easier to work around when known beforehand.
If you are pregnant, trying to conceive, or breastfeeding, say so before the injection is drawn up. The decision then belongs to you, your eye doctor, and the doctor looking after your pregnancy, weighed together. The same is true if you are due other surgery soon. There is no single right answer here, and it is not a decision to settle from a page like this one.
After the Injection, and Between Injections
Most of what you notice afterwards is expected and short lived. The risks listed under informed consent for an eye injection include pain, a feeling of something in the eye, watering, and bleeding under the clear surface layer on the white of the eye3. Floaters after the injection are common enough that clinicians reassure patients about them, and the antiseptic used on the eye is washed off well at the end3. Gritty and sore for a day is ordinary. Worsening over several days is not.
Most people go back to ordinary life the same day or the next. Vision may be blurry for a few hours, so arrange a ride home for your first injection until you know how you react. Avoid rubbing the eye, and avoid dusty places, for a couple of days. Ask your team about swimming.
If an authorization delay pushes your date back, tell the office that the appointment is at risk rather than waiting for them to notice. Ask whether an expedited request applies, and whether a medicine your plan already covers could keep you on schedule meanwhile. Keeping the rhythm of treatment is usually what your team is working towards.
Risks, Delays, and the Realistic Picture
The honest answer sits between panic and shrugging. In one study of 99 eyes whose injections were delayed by at least 21 days, with an average delay of 44 days, vision at the first visit after the delay was worse than in eyes treated on time, and the retina was thicker, but by the 16 week visit neither difference remained, and the authors concluded the changes seen were reversible7. That is one study, in one condition. It suggests a short slip is usually recoverable, not that delays are harmless.
Knowing the spread helps you judge when to push. In a closer look at 725 of the delayed approvals in the 9 practice study, 173 were approved within 1 day, 115 within 2 to 3 days, 156 within 4 to 7 days, 191 within 8 to 31 days, and 90 after more than 31 days2. A wait of a few days is common. A wait running past a month is the point to escalate rather than keep waiting quietly.
Every injection carries a small risk of infection inside the eye, called endophthalmitis. In one study of 101,932 same day injections given in both eyes, in 5,890 patients over 5 years, there were 28 cases of infection inside the eye, and no patient had it in both eyes. Other studies report rates ranging from under 1 case up to about 7 cases for every 10,000 injections3. Those are rates for each injection, not for each person. So it is uncommon, and it is treatable when caught early, which is why the same day warning signs at the top of this page matter. Other serious complications include a retinal tear or detachment, cataract formation, and raised pressure inside the eye3.
Approval is a coverage decision, not a bill. You may still have a copay, coinsurance, or an unmet deductible for the drug and the visit. Ask the billing staff for an estimate before your next injection rather than after. If cost is a barrier, say so early, because assistance programs exist and take time to arrange.
Questions People Ask About Injection Authorizations
No. It is a cost control step applied to a category of medicine, not a judgment about your eye. Carriers apply it to anti-VEGF drugs because of the volume and high dollar cost involved1. About 96 of every 100 requests in a study of 9 retina practices were approved2. The far more common outcome is approval with a wait attached, rather than a refusal on clinical grounds.
Not if you are already on the medicine. People already taking a Part B covered drug cannot be required to switch to their Medicare Advantage plan's preferred drug, because step therapy applies only when someone starts a new medicine6. For a new start, a plan may require the lower cost drug first. Ask your doctor to record clearly how you responded to anything you have already tried, because that record is what an exception rests on.
Because approvals expire and policies move. Prior authorization policies vary significantly by carrier and change frequently1, and 64 of every 100 requests in the 9 practice study were reauthorizations for a medicine already being used2. A new plan year, a new preferred drug list, or a new biosimilar on the market can all restart the process. It is rarely about anything that changed in your eye.
That is a question for your own retina team, because it depends on your condition and how active it is. In one study of unplanned delays averaging 44 days, vision was worse at the first visit afterwards but the difference had gone by 16 weeks7. That is reassuring about a short slip and says nothing about a long one. Tell your team the date you are at risk of missing, and let them decide.
Sometimes, but ask carefully before you commit. The office can tell you the self pay price for the drug and the procedure, and whether paying privately affects your plan's records of what you have tried. That matters, because a documented treatment history is what future authorizations and appeals are built on. Ask about assistance programs in the same conversation.
Not necessarily. Your doctor may be able to proceed with a medicine your plan already covers while the appeal runs, so ask about that instead of assuming everything stops. You have the right to request an exception and to appeal a refusal, and to ask for that appeal to be decided on an expedited timeline if your doctor believes waiting could seriously harm your health6. Ask your office to file both at once where that is possible.
More Questions About Injections and Coverage
Off-label is not the same as not studied or not good. Bevacizumab (Avastin) is listed as off-label among the medicines given by injection into the eye3. Off-label prescribing is legal and routine across medicine, and this drug has been used in eyes for many years. Whether it suits your eye is a clinical judgment for your retina specialist. Ask them why they favor one option over another for you.
A biosimilar is a close copy of an existing biologic medicine, made once the original loses exclusivity. Biosimilar versions of ranibizumab and aflibercept, such as ranibizumab-nuna (Byooviz) and aflibercept-ayyh (Pavblu), are among the medicines given as an injection into the eye3. Plans often prefer them because they cost less. If a switch is proposed, ask your doctor whether it suits your condition, and ask the office to note your response after the change so any problem is documented.
There is no single schedule, and yours will be set by how your retina responds. People may need injections and follow up every month early in treatment, and once the disease is stable some doctors extend the interval between injections3. Nobody can tell you a final number at the start. Ask at each visit what your team is aiming for, and what would make them shorten or lengthen the gap.
Possibly, and there is a specific proposal in play. CMS issued a proposed rule in April 2026 that would apply prior authorization standards to drugs, with a proposed compliance date of October 1, 2027. It does not propose new decision timeframes for Medicare Advantage organizations or Part D sponsors, citing the requirements that already apply to Part B and Part D drugs5. It is a proposal, not settled policy, and nothing changes unless it is finalized. Until then, plan around the rules in force today rather than tomorrow's.
- When does my current authorization expire, and which medicine does it cover?
- Does my plan require step therapy for the medicine you recommend?
- If my request is refused, will you file an exception and an expedited appeal?
- What is documented about the medicines I have already tried, and how I responded?
- If the authorization is delayed, is there a covered option that keeps me on schedule?
- What should I watch for after each injection that would need a same day call?
- American Academy of Ophthalmology, practice management resources (2026). Prior Authorization for Retina (practice management resource).
- JAMA Ophthalmology, prospective multicenter quality improvement study across 9 US private retina practices, January to June 2022 (2024). Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices.
- EyeWiki, American Academy of Ophthalmology (2026). Intravitreal Injections (EyeWiki).
- KFF (Kaiser Family Foundation), policy analysis of the CMS Interoperability and Prior Authorization final rule (CMS-0057-F) (2024). Final Prior Authorization Rules Look to Streamline the Process, but Issues Remain.
- Applied Policy, regulatory analysis of the CMS Interoperability Standards and Prior Authorization for Drugs proposed rule (CMS-0062-P) (2026). CMS Proposes Interoperability Standards and New Prior Authorization Requirements for Drugs.
- National Council on Aging (NCOA), consumer guidance, published 18 December 2025 (2025). Medicare Part B Step Therapy: How Part B Drug Coverage Works in Medicare Advantage.
- Scientific Reports, retrospective cohort study of unplanned anti-VEGF injection delays (2023). The effect of a brief, unplanned treatment delay on neovascular age-related macular degeneration patients: a retrospective cohort study.